Search for tag: "heart failure"

Dr. Miller: About 32 years ago, Barney Clark had the first artificial heart implanted here at the University of Utah. We're going to talk about how things have changed since then on The Scope Radio. This is Dr. Tom Miller.

Announcer: Medical news and research from the University of Utah physicians and specialists you can use for a happier and healthier life. You're listening to The Scope.

Dr. Miller: I'm here with Dr. Craig Selzman. He's an Associate Professor of Cardiothoracic Surgery in the Department of Surgery here at the University of Utah, and Craig is an expert in heart transplantation as well as ventricular assist devices, which are the new artificial hearts.
About 32 years ago, Barney Clark was the first man to undergo an artificial heart implantation, and that was here at the University of Utah. Now a lot has changed since then, I think. Dr. Selzman, can you talk to us about what's new with artificial hearts?

Dr. Selzman: Since that time, so much has happened. It's been in two or three different areas, and the first area is just the technology.

Dr. Miller: That's got to have changed tremendously.

Dr. Selzman: It's huge.

Dr. Miller: I remember the pictures of Barney Clark. The pumps were huge. They had to wheel it around with Barney Clark. It was noisy. It was loud. It was terrible.

Dr. Selzman: It's a Zamboni machine. We still have one here in the hospital, if necessary, to clean the ice outside. But the deal now is that we have these pumps so small and they're very patient-friendly so that the patients can actually go home. They can do everything. They can play 18 holes of golf, walking. You name it; they can do it.
The one thing that is a little bit difficult is there's electricity going through this; they're not going for a swim any time soon, but that's even changing. We have pumps now that allow people to have artificial heart support that can actually go swimming with internal batteries and stuff. So it's been huge.

Dr. Miller: So are the pumps still external to the body, or are they within the body now?

Dr. Selzman: They're all within the body. We still have some that are used externally. Those are used for really the sickest of patients that we're really just trying to do whatever we can to save their lives. But in terms of folks that you want to actually go home and regain life, the thing about a lot of this field is that the chances of you having a long life with advanced heart failure is low. Probably the patients we're talking about, less than 10% are alive at two years.

Dr. Miller: I mean, that's as bad as many cancers.

Dr. Selzman: It's metastatic cancer. It's basically the same thing. I use an analogy a lot, and the one thing that the VADs have done in this artificial technology is that it's the therapy that is so much better than chemotherapy, meaning that you can put somebody on with an advanced cancer, and you might buy another two, three year, four months. We're talking about buying five to 10 years. And not only just years, but also quality years. These patients are back with their families. They're going back to work. They're living life. It's amazing.

Dr. Miller: Craig, does this mean that actually having a heart transplant may become obsolete?

Dr. Selzman: Ah, that's a great question, and it's one of the current debates within our community because the life expectancy, the one year survival rate for patients that are getting these machines is almost as good as getting a heart transplant. The problem with heart transplant: great therapy. There are just not enough of them.
For the last 25 years, we've done about 2,000-2,500 hearts a year in the United States, but there are probably 80- to 100,000 folks that need it today. So these pumps have really filled that gap. Early on, because the pump technology wasn't quite so good, you'd have complications. But now the complication rates are actually very manageable and the survival is quite good. One year survival is over 90% right now.

Dr. Miller: I remember in the Barney Clark days that that clots arising from the use of that type of pump were a real problem. That's pretty much eliminated now, is that right?

Dr. Selzman: Whenever you have blood that goes through a washing machine or a Kenmore or a Maytag, it's just not normal. And so we still are faced with this complex problem of hemostasis, thrombosis, and anti-coagulations. For the most part for these pumps, you will be taking some blood thinner medicines.

Dr. Miller: But the risk of having a clot is lower?

Dr. Selzman: It's much lower. I mean, it hearkens back to the old heart valve days where we used to have that had a ball that would go up and down, the old Bjork-Shiley valves and stuff. We don't use those any more, and so the whole field is new.

Dr. Miller: The whole technology.

Dr. Selzman: Yeah.

Dr. Miller: What does the future look like in terms of these devices? I mean, do you see these devices becoming smaller, like calculators becoming smaller and smaller?

Dr. Selzman: Yeah. I think there are two or three things that are going to really make a difference here, and you could actually trace back. If you look at the pacemaker defibrillator field, defibrillators used to be these big giant things that you used to put in the abdominal cavity, and now they're these little things below your collarbone.
So the same things happened in the VAD world. They're getting smaller and smaller, and because they're getting smaller and smaller, the complications are less and less, you're actually going to start putting these things in patients that are less sick to try to get them off this spiral of decline that happens with heart failure. So size definitely better, complication rate less. And then the main thing that's coming from an industrial standpoint is power. So just like you're trying to get batteries in that 747, or what was it, the 757, the lithium battery was the only bad thing.

Dr. Miller: Exactly.

Dr. Selzman: So they're starting to do the same thing with these VADs. And so a lot of the original DeBakey pump, believe it or not, was a collaboration with N.A.S.A. to help do these things.

Dr. Miller: Spinoff technology.

Dr. Selzman: Yeah, so there's a lot of cross collaboration there. The interesting thing I think really where the field is going, it's not so much about the pump because the pumps are getting better and better. But it's about the patient and the biology of the patient. And our goal is not to actually put the pump in to have them have it for the rest of their life or for them to get a transplant, but actually to get better so that we can remove the pump.
So how do we do that? Well, we're going to recondition the heart, probably use other biologic therapies to help us. So the main thing that I see the field going in the next five to 10 years is not so much about a pump, but about a patient that has a bad heart. How do you make that heart better with the assistance of a heart pump so that you can actually remove it so that patients can live long lives that way?

Announcer: We're your daily dose of science, conversation and medicine. This is The Scope. This is the University of Utah Health Sciences Radio.

Craig Selzman: This is Craig Selzman. I am an Associate Professor of Surgery in the Division of Cardiothoracic Surgery here at the University of Utah, and I am the surgical director of our Heart Transplant Program and our Mechanical Circulatory Support and Artificial Heart Program.

Host: In the news, we've heard Randy Travis had something called cardiomyopathy. Am I pronouncing that right?

Craig Selzman: Correct.

Host: What exactly is that?

Craig Selzman: Cardiomyopathy is a generalized word. Cardio, heart. Myo, muscle. Opathy, not working so good. So basically it means that the heart muscle itself is not working so well.

Host: And there's a virus that causes this. Is that correct?

Craig Selzman: There are a lot of different things that can cause a cardiomyopathy. So the word that leads before cardiomyopathy describes why it had happened. It could be because of bad blood flow. We would call that ischemic cardiomyopathy. It could be because of something that we have no idea, which we would call it idiopathic cardiomyopathy. But if we think it's a virus, then we'll call it a viral cardiomyopathy.

Host: Yeah. And in the case of Randy Travis, it indeed is.

Craig Selzman: Well, that is the presumption.

Host: Okay.

Craig Selzman: To the best of my knowledge, it hasn't been confirmed. I think that's what everybody thinks is going on.

Host: All right. And this condition causes the heart to weaken, if I'm correct?

Craig Selzman: That's correct.

Host: And then what's the cure for that? What did they actually do in his case?

Craig Selzman: Well, the cure for the majority of patients, 80, 85, 90% is absolutely nothing. It's just supportive care. But there is this very small group of patients that go into cardiovascular collapse. That means that the heart muscle is unable to pump enough blood around the body to get to the brain, to the kidneys, and to other organs and such that they need extra help. A lot of the times, that extra help can be managed with medicines in the vein, but if that doesn't work, sometimes you actually have to use mechanical means to do that. And that's what happened for Randy Travis.

Host: Is this an invasive surgery? Do they have to open his chest to get it in?

Craig Selzman: No. This is not really surgery. What it is is basically a catheter that's snaked up through one of the blood vessels that's easily accessible through the skin in the groin. So we call it a percutaneous heart pump. It's not really surgery in the classic sense.

Host: But you're hosing that thing up through the groin all the way to the heart. How difficult of a procedure is that?

Craig Selzman: Just like a lot of things in life, 85% is very straightforward, and 10 to 15% can be challenging.

Host: Sure. But for the most part . . .

Craig Selzman: Conceptually, it's very straightforward. Technically, it's very straightforward, for the most part.

Host: And nowadays, it's fairly common?

Craig Selzman: Fairly common. We did one on Monday.

Host: All right. The device that they placed, is he going to have to have that in him for the rest of his life?

Craig Selzman: No. This is a temporary device. It's actually meant for really short periods of support. It could be hours or days.

Host: Okay.

Craig Selzman: The hope here, with someone with his kind of situation, is using this pump to try to support his organs, giving them blood flow while the doctors down there figure out is his heart muscle going to get better or not.

Host: Gotcha.

Craig Selzman: And what this pump does or what any mechanical pump does is it allows the heart to just rest because it takes over, giving blood flow to the rest of the body. If you don't have it, his heart is having to work so hard and it's just tired. By doing this, it allows the heart to relax and just kind of get a little bit of rest, get some new energy.

Host: Kind of like any other muscle, you're just giving it a chance to recover?

Craig Selzman: That's right. So by doing that, it gives the physicians a chance to see whether or not his heart will recover or not. If the heart recovers, let's take the first situation, you can just pull this thing out, and then it carries on. The majority of patients that have this problem can go onto live normal, active lives. A subgroup of those patients that won't get better will kind of limp along a little bit and become heart failure patients. And then there's this other category of patients that maybe will not be able to survive without a pump like this. In that situation, what we would do is we would switch this percutaneous pump to something that's a little bit more durable.

Host: Okay. So is he looking at some lifestyle changes if he recovers?

Craig Selzman: I don't know enough the guy to, I can imagine.

Host: Some alcohol use has been recorded.

Craig Selzman: He's lived a hard life in many ways, and that could be contributing to this. And certainly if you live a cleaner life, sometimes you can reverse a lot of this stuff, especially with the heart.

Host: Would a lifestyle change have prevented this from happening in the first place?

Craig Selzman: Potentially. But if it's truly viral cardiomyopathy, this can attack anybody. I mean, in the pediatric community, you see this much more frequently than in the adult community. This is a very promiscuous disease. The virus doesn't care who it attacks. Is your heart maybe more susceptible to it? Is somebody's heart more susceptible to it? Possibly.

Host: What would cause that?

Craig Selzman: Let's say he had lived a hard life and had an alcoholic cardiomyopathy, which is a type of thing that happens. For other folks, after pregnancy have a thing called peripartum cardiomyopathy that makes their heart a little bit weaker, so they're more susceptible to having other insults attack their heart.

Host: What kind of recovery time would you look for after a procedure like Randy Travis had?

Craig Selzman: I would hope that in the next three to five days that they'll have a sense of whether or not the left ventricle, there are two main pumping chambers of the heart, the left ventricle and the right ventricle. This pump is supporting his left ventricle. The hope would be, then, in a three to five period, that they would have some idea of which of those tiers he's in. Is he going to be somebody that's going to get completely better and pull the pump, not really better but let's pull the pump and see how he does without the pump, and then the third one being it isn't going to work and we're going to have to do something else. But usually within three to five days, you have an idea of what's going on.